ロード中...
Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
INTRODUCTION: Combined anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 blockade induced high rates of immune‐related adverse events in patients with renal cell carcinoma. However, the safety of reinitiating anti‐programmed cell death 1 monotherapy for patients who discontinued comb...
保存先:
| 出版年: | IJU Case Rep |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7469840/ https://ncbi.nlm.nih.gov/pubmed/32914066 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/iju5.12173 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|